Results 61 to 70 of about 539,046 (150)

Synaptic vesicle glycoprotein 2A modulates vesicular release and calcium channel function at peripheral sympathetic synapses

, 2014
Synaptic vesicle glycoprotein (SV)2A is a transmembrane protein found in secretory vesicles and is critical for Ca2+-dependent exocytosis in central neurons, although its mechanism of action remains uncertain. Previous studies have proposed, variously, a
Vogl, Christian, Foerch, Patrik, Patrik Foerch, Whalley, Benjamin J., Christian Wolff, Gary J. Stephens, Daniels, Veronique, Danis, Benedicte, Christian Vogl, Sumiko Mochida, Wolff, Christian, Veronique Daniels, Benedicte Danis, Shota Tanifuji, Mochida, Sumiko, Benjamin J. Whalley, Tanifuji, Shota, Stephens, Gary J.   +17 more
core   +1 more source

Structural pharmacology of SV2A reveals an allosteric modulation mechanism in the major facilitator superfamily

Nature Communications
The synaptic vesicle glycoprotein 2A (SV2A), a member of the major facilitator superfamily (MFS), is a key target for antiseizure medications and a biomarker for synaptic density imaging.
Shabareesh Pidathala, Xiao Chen, Yaxin Dai, Long N. Nguyen, Christoph Gorgulla, Yiming Niu, Fangyu Liu, Chia-Hsueh Lee   +7 more
doaj   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, Volume 67, Issue 10, Page 5075-5125, October 2026.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats [PDF]

, 2019
Synaptic dysfunction is hypothesised to play a key role in schizophrenia pathogenesis, but this has not been tested directly in vivo. Here, we investigated synaptic vesicle glycoprotein 2A (SV2A) levels and their relationship to symptoms and structural ...
Shatalina, Ekaterina, Cotel, Marie-Caroline, Onwordi, Ellis Chika, Halff, Els F, Howes, Oliver D., Bonsall, David, Whitehurst, Thomas, Gunn, Roger N., Marques, Tiago Reis, Halff, Els F., Vernon, Anthony C.; id_orcid, Reis Marques, Tiago, Creeney, Hannah, Rogdaki, Maria, Gunn, Roger, Natesan, Sridhar, Vernon, Anthony, Rabiner, Eugenii, Cotel, Marie-Caroline; id_orcid, Bonsall, David R., Mansur, Ayla, Wells, Lisa, Howes, Oliver, Wells, Lisa A   +23 more
core   +1 more source

Human biomarker navigator

iMeta, Volume 5, Issue 5, October 2026.
The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li, Qian Zhang, Zijie Wang, Zeping Gui, Jing Liu, Jingda Li, Maojun Jiang, Zukang Chang, Qingqing Han, Bendong Yang, Tariq Saeed, Jun Li, Jinghan Jia, Chenghu Song, Tong Shao, Tianhuan Peng, Xueying Zhang, Pingping Guo, Jun Luo, Gangao Yang, Yuan Wan, Gokhan Zengin, Quan Yuan, Lingru Li, Xiaohui Fan, Yang Luo, Lvyun Zhu, Yanfei Zheng, Wenjun Mao, Wenlong Sun   +29 more
wiley   +1 more source

Synaptic Vesicle Protein 2A Expression in Glutamatergic Terminals Is Associated with the Response to Levetiracetam Treatment

, 2021
Synaptic vesicle protein 2A (SV2A), the target of the antiepileptic drug levetiracetam (LEV), is expressed ubiquitously in all synaptic terminals. Its levels decrease in patients and animal models of epilepsy.
Julieta G. Mendoza-Torreblanca, Juan Luis Chávez-Pacheco, Bryan Víctor Phillips-Farfán, Itzel Jatziri Contreras-García, Luz Adriana Pichardo-Macías, Mercedes Edna García-Cruz, Gisela Gómez-Lira   +6 more
core   +1 more source

Drug characteristics derived from kinetic modeling: combined 11C-UCB-J human PET imaging with levetiracetam and brivaracetam occupancy of SV2A

EJNMMI Research, 2022
Background Antiepileptic drugs, levetiracetam (LEV) and brivaracetam (BRV), bind to synaptic vesicle glycoprotein 2A (SV2A). In their anti-seizure activity, speed of brain entry may be an important factor.
Mika Naganawa, Jean-Dominique Gallezot, Sjoerd J. Finnema, Ralph Paul Maguire, Joël Mercier, Nabeel B. Nabulsi, Sophie Kervyn, Shannan Henry, Jean-Marie Nicolas, Yiyun Huang, Ming-Kai Chen, Jonas Hannestad, Henrik Klitgaard, Armel Stockis, Richard E. Carson   +14 more
doaj   +1 more source

Multiscale Circuit Architecture Associated With Memory Dysfunction in Temporal Lobe Epilepsy

Advanced Science, Volume 13, Issue 53, 24 September 2026.
A multiscale precision‐mapping framework reveals that memory impairment in temporal lobe epilepsy arises from the convergence of focal medial temporal pathology, strategic white matter disconnection, and limbic‐centered metabolic network dysfunction.
Jiajie Mo, Qiwen Yuan, Pengfei Zhang, Lin Sang, Zhong Zheng, Baotian Zhao, Xiu Wang, Chao Zhang, Wenhan Hu, Xiaoqiu Shao, Jianguo Zhang, Ruijin Yang, Kai Zhang   +12 more
wiley   +1 more source

Neuropathic Pain: From Mechanisms to Therapeutic Interventions [PDF]

MedComm (2020)
Neuropathic pain arises from peripheral nerve injury, central sensitization, neurotransmitter imbalance, neuroimmune activation, and maladaptive circuit remodeling. Clinical phenotyping and multimodal imaging can identify dominant peripheral and central mechanisms.
Dai Y, Tan M, Yuan M, Zhou H, Xie Q, Zeng J, Yang Y, He X, Song S.   +8 more
europepmc   +2 more sources

GMP-compliant automated radiosynthesis of [18F] SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2 A (SV2A)

EJNMMI Radiopharmacy and Chemistry
Abstract Background A novel positron emission tomography (PET) imaging tracer, [18F] SynVesT-1, targeting synaptic vesicle glycoprotein 2 (SV2A), has been developed to meet clinical demand. Utilizing the Trasis AllinOne-36 (AIO) module, we’ve automated synthesis to Good Manufacturing Practice (GMP) standards, ensuring sterile, pyrogen-free ...
Lijuan Chen, Xiaochen Li, Yao Ge, Huiqiang Li, Ruili Li, Xiaosheng Song, Jianfei Liang, Weifeng Zhang, Xiaona Li, Xiaoqi Wang, Yunjuan Wang, Yaping Wu, Yan Bai, Meiyun Wang   +13 more
openaire   +3 more sources